Literature DB >> 20817613

Postictal affective episodes.

Andres M Kanner1, Michael Trimble, Bettina Schmitz.   

Abstract

Despite their recognition two centuries ago, postictal depression symptoms (PDSs) and episodes (PDEs) continue to be ignored by most clinicians in their evaluation of patients with epilepsy. And yet, PDSs are relatively frequent in patients with pharmacoresistant epilepsy, having been identified in almost 50% of patients with a median duration of 24 hours. PDSs may be the expression of symptoms restricted to the postictal period (defined as the first 5 days following a seizure) and/or may be the expression of postictal exacerbation in severity of interictal symptoms of depression. In fact, a past history of depressive and anxiety disorders has been associated with the occurrence of PDSs and PSEs. PDSs and PSEs often occur together with postictal symptoms of anxiety, and the occurrence of PDSs has been associated with more severe postictal cognitive deficits. The occurrence of PDSs and PDEs has not been associated with any epilepsy-related variable (location of seizure focus, MRI findings, type of antiepileptic drug). Prevention of PDSs and PDEs can be achieved only with seizure freedom, and preliminary uncontrolled data suggest that being on antidepressant medication does not protect patients from experiencing these types of symptoms.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20817613     DOI: 10.1016/j.yebeh.2010.06.024

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  11 in total

Review 1.  Depression in epilepsy: a critical review from a clinical perspective.

Authors:  Christian Hoppe; Christian E Elger
Journal:  Nat Rev Neurol       Date:  2011-07-12       Impact factor: 42.937

Review 2.  [Coexistent depressive and anxiety disorders in epilepsy and multiple sclerosis: a challenge to neuropsychiatric practice].

Authors:  Hans-Peter Kapfhammer
Journal:  Neuropsychiatr       Date:  2014-05-20

Review 3.  Depressive syndromes in neurological disorders.

Authors:  Julian Hellmann-Regen; Dominique Piber; Kim Hinkelmann; Stefan M Gold; Christoph Heesen; Carsten Spitzer; Matthias Endres; Christian Otte
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-11       Impact factor: 5.270

Review 4.  [Depression and neurological diseases].

Authors:  D Piber; K Hinkelmann; S M Gold; C Heesen; C Spitzer; M Endres; C Otte
Journal:  Nervenarzt       Date:  2012-11       Impact factor: 1.214

Review 5.  [Depression and epilepsy : Two clinical pictures with common causes?].

Authors:  M Borgmann; M Holtkamp; M Adli; J Behr
Journal:  Nervenarzt       Date:  2016-07       Impact factor: 1.214

6.  An investigation into the psychosocial effects of the postictal state.

Authors:  Colin B Josephson; Jordan D T Engbers; Tolulope T Sajobi; Nathalie Jette; Yahya Agha-Khani; Paolo Federico; William Murphy; Neelan Pillay; Samuel Wiebe
Journal:  Neurology       Date:  2016-01-27       Impact factor: 9.910

7.  Effect of the Anti-depressant Sertraline, the Novel Anti-seizure Drug Vinpocetine and Several Conventional Antiepileptic Drugs on the Epileptiform EEG Activity Induced by 4-Aminopyridine.

Authors:  Maria Sitges; Blanca Irene Aldana; Ronald Charles Reed
Journal:  Neurochem Res       Date:  2016-01-30       Impact factor: 3.996

8.  What is Depression in Epilepsy?

Authors:  Christian E Elger; Christian Hoppe
Journal:  Front Neurol       Date:  2011-12-07       Impact factor: 4.003

9.  Sertraline reduces IL-1β and TNF-α mRNA expression and overcomes their rise induced by seizures in the rat hippocampus.

Authors:  María Sitges; Carlos D Gómez; Blanca I Aldana
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

10.  Severe intermittent anxiety attacks. A diagnosis challenge in temporal lobe epilepsy.

Authors:  Abdulaziz T Alshomrani; Radwan M Zaidan; Yosef T Abdulmalik; Nader M Alrahili
Journal:  Neurosciences (Riyadh)       Date:  2017-01       Impact factor: 0.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.